The U.S. Food and Drug Administration (FDA) has approved Merilog (insulin-aspart-szjj), a Novolog (insulin aspart) biosimilar, for the control of glycemia in adults and pediatric patients with diabetes mellitus. Merilog is the first FDA-approved rapid-acting insulin biosimilar and is available as a 3 mL prefilled pen and a 10 mL multiple-dose vial. Merilog reduces mealtime blood sugar surges, allowing for improved control of diabetes.
The study, titled “The protective effect of sodium-glucose cotransporter-2 inhibitor on left ventricular global longitudinal strain in patients with type 2 diabetes mellitus according to disease duration,” investigates the impact of SGLT2 inhibitors on heart function in type 2 diabetes patients.
The study investigated the effects of canagliflozin (CANA), a sodium-glucose transporter-2 inhibitor (SGLT2i), on bone health using genetically heterogeneous UM-HET3 mice. CANA is typically used to lower blood glucose levels independently of insulin but also induces various metabolic changes, including weight loss and impaired bone integrity. The research aimed to understand how CANA affects bone metabolism, given that SGLT2 is not expressed in osteoblasts or osteocytes, which are crucial for bone remodeling.
Diabetic emergencies remain a significant healthcare challenge in developing countries, presenting a complex intersection of medical, social, and economic issues. This systematic review highlights the concerning prevalence and impact of acute diabetic complications in resource-limited settings.
The MeMeMe randomized trial studied whether metformin (1,700 mg/day), with or without a Mediterranean diet (MedDiet), could reduce the incidence of major noncommunicable diseases (NCDs) in individuals with metabolic syndrome (MetS). The trial included 1,442 participants, randomly assigned to one of four groups: metformin alone, metformin + MedDiet, placebo alone, or placebo + MedDiet. The participants were followed for an average of three years, with the primary outcome being the cumulative incidence of type 2 diabetes, cardiovascular diseases, and cancer.
This systematic review and meta-analysis assessed the burden of micronutrient deficiencies among patients with type 2 diabetes (T2D), analyzing 132 studies with 52,501 participants. Micronutrient deficiencies in T2D were 45.30%, with vitamin D (60.45%), magnesium (41.95%), and B12 (28.72%) most common. Women were more affected.
